Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis

Feldman, Steven R.; Zhao, Yang; Shi, Lizheng; Tran, Mary Helen

doi:10.18553/jmcp.2015.21.10.874

Cited by 54 publications

(71 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although multiple biologics for psoriasis are available, many patients still experience residual disease and impaired functioning . With established psoriasis biologics, especially anti‐TNF agents, dose escalation is common and discontinuation rates are high . New agents should demonstrate an advantage regarding efficacy and/or safety compared with existing agents.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

et al. 2017

View full text Add to dashboard Cite

SummaryBackground Significant advances have been made in the treatment of moderate-tosevere plaque psoriasis with biological therapies; however, these agents may not work equally in all populations. Objectives To evaluate the efficacy of guselkumab in patient subgroups with moderate-to-severe psoriasis from the pooled guselkumab VOYAGE 1 and VOYAGE 2 phase III studies. Methods Using data from the pooled VOYAGE 1 and VOYAGE 2 psoriasis studies, analyses were performed to evaluate the consistency of efficacy [Investigator's Global Assessment (IGA) 0/1 (cleared or minimal psoriasis) and IGA 0 (cleared)] across subpopulations defined by demographics, baseline disease characteristics and previous psoriasis treatment. Results A total of 1829 patients were randomized. Baseline demographics, disease characteristics and previous psoriasis treatment were comparable across treatment groups in the pooled population. Guselkumab, an anti-interleukin (IL)-23 monoclonal antibody that binds to the p19 subunit of IL-23, provided substantial benefit across almost all subpopulations, with greater proportions of patients achieving IGA 0/1 vs. placebo at week 16, and vs. adalimumab (an antitumour necrosis factor monoclonal antibody) at week 24. Patients treated with guselkumab achieved greater efficacy (IGA 0/1 and IGA 0) compared with adalimumab at week 24 across all weight quartiles, most notably among patients weighing ≥ 100 kg. Conclusions This analysis demonstrates a high degree of efficacy with guselkumab treatment compared with placebo at week 16 and with adalimumab at week 24 among broad subpopulations of patients with varying baseline demographics, disease characteristics and previous psoriasis treatments.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Several epidemiological studies have investigated the relationship between psoriasis and depression or SIB (Table 1). 11,[26][27][28][29][30][31][32][33][34][35][36][37][38][39][40] Because of differences in study design, notably in patient populations and measurement methods (e.g. self-reported, diagnostic codes), reported rates of psychiatric comorbidities vary.…”

Section: Mental Health Disorders In Patients With Psoriasismentioning

confidence: 99%

Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression

Koo

Marangell

Nakamura

et al. 2017

Acad Dermatol Venereol

168

152

View full text Add to dashboard Cite

Psoriasis can be a socially isolating disease due to debilitating physical symptoms and the stigma patients feel because of the appearance of their skin. Mental health comorbidities such as anxiety, depression and suicidal ideation and behaviour (SIB) are prevalent in patients with psoriasis. Patients with mild psoriasis can experience psychiatric comorbidities; however, disorders such as depression and SIB are more common in patients with severe psoriasis or psoriatic arthritis. Psychiatric disorders can both result from and contribute to progression of psoriasis, suggesting that psoriasis and psychiatric conditions, such as depression, may have overlapping biological mechanisms. Proinflammatory cytokines such as interleukin (IL)-1 and IL-6 are elevated in both psoriasis and depression, indicating that the inflammatory process may be involved in the progression of both diseases. Elevated cytokine levels in the central nervous system cause physiologic and biochemical changes that may contribute to the development of depression. In this review of the literature, we discuss the evidence that supports the association of psoriasis with mental health disorders and the tools used to detect the presence of these comorbidities. Additionally, we review the most prominent hypotheses on the mechanisms by which the inflammatory response and elevated cytokines can cause depression. These results highlight the role that systemic inflammation plays in the various mental health comorbidities associated with psoriasis, including depression and SIB.

show abstract

“…12 An Australas Journal of Dermatology paper reports the rate of hypertension in psoriasis patients to be 30%, 14 as does a Brazilian study. 18 The study of the Czech registries reports the prevalence at 35.2%, 8 and similarly, Schaarschmidt et al listed the prevalence of hypertension at 31.5%. 9 Similar to the Czech study, a study of over 48,000 psoriasis patients and over 200,000 controls, spanning the years 1994-2009 showed a baseline of 15.39% prevalence of hypertension (compared to nearly 15% in the controls).…”

Section: Hypertensionmentioning

confidence: 94%

Review of the Prevalence of Cardiovascular and Metabolic Comorbidities of Psoriasis

Vebman¹,

Choy²,

Yao³

2020

J of Skin

View full text Add to dashboard Cite

Introduction:-Psoriasis is a common disease that is linked with several other diseases. Our goals were to analyze and present literature on prevalence of various psoriatic comorbidities, and provide an estimate of what percent of psoriasis patients might have or develop Myocardial/cardiovascular/heart disease, stroke, diabetes, obesity, hypertension, or metabolic syndrome.Method:-To collect the results, we searched PubMed to identify papers that studied the frequency of the most common comorbidities of psoriasis. We used about 20. The search terms used were the particular comorbidity (or synonyms) and psoriasis. Papers were selected where the prevalence data were listed by percentages of the studied population. Prevalence data from each paper were collected and charted, and then compared. We did not use data that concerned Psoriatic Arthritis. We also recorded outliers, where frequencies did not fit with the other data found.Results:-Results for prevalence of myocardial/cardiovascular/heart disease were mixed, varying by age and severity of disease. There are few papers on prevalence of stroke, but our review suggests risk of stroke increases with severity of psoriasis. The prevalence of diabetes was largely between 10% and 20%. Obesity’s prevalence was mostly between 15% and 30%, while hypertension hovered around 30%, and metabolic syndrome prevalence was mostly between 27% and 50%.Conclusions:-There are many comorbidities of psoriasis. The complex interaction between cutaneous inflammation and heart disease, stroke, diabetes, hypertension and metabolic syndrome raises many questions about cause and effect or simple association.

show abstract

Economic and Comorbidity Burden Among Patients with Moderate-to-Severe Psoriasis

Abstract: Compared with PsO- and PsA-free controls, moderate-to-severe PsO patients were more likely to have selected comorbidities and higher health care utilization and costs.

Cited by 54 publications

References 36 publications

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies

Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression

Review of the Prevalence of Cardiovascular and Metabolic Comorbidities of Psoriasis

Contact Info

Product

Resources

About